Abstract
Migraine is a debilitated disorder that is often under diagnosed in clinical practice. Early detection of migraine leads to outstanding improvements in patients’ quality of life. New researchers had developed the central sensitization and cutaneous allodina in chronic migraine which is helpful in early treatment approach with triptans and other agents in acute migraine episodes. Right now, five agents are accepted by US food and drug administration (FDA) for migraine prevention. They are namely Divalporex sodium, Propranolol, Timolol maleate, Topiramate and Methysergide. For so many years, other medications have been used to prevent migraine with not much more success rate. They are Tricyclic anti depressants, anti epileptic agents, Nonsteroidal anti-inflammatory drugs (NSAIDs), Selective serotonin reuptake inhibitors (SSRIS), Calcium channel blockers and muscle relaxants. Calcitonin gene related peptide antagonist, Ditans, Botulinum toxin type A, Orexin receptor antagonists etc were the recent novel agents in the treatment and management of migraine. These novel agents showed more affect than other medications in the acute and prophylactic management of migraines. They play a pivotal role in the standard care for migraine treatment that will improve the patient quality of life with better outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
